SCFFbxo9 and CK2 direct the cellular response to growth factor withdrawal via Tel2/Tti1 degradation and promote survival in multiple myeloma (original) (raw)

• Jorgensen, P. & Tyers, M. How cells coordinate growth and division. Curr. Biol. 14, R1014–R1027 (2004).
  Article CAS Google Scholar
• Wullschleger, S., Loewith, R. & Hall, M. N. TOR signaling in growth and metabolism. Cell 124, 471–484 (2006).
  Article CAS Google Scholar
• Zoncu, R., Efeyan, A. & Sabatini, D. M. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 12, 21–35 (2011).
  Article CAS Google Scholar
• Mendoza, M. C., Er, E. E. & Blenis, J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem. Sci. 36, 320–328 (2011).
  Article CAS Google Scholar
• Laplante, M. & Sabatini, D. M. mTOR signaling in growth control and disease. Cell 149, 274–293 (2012).
  Article CAS Google Scholar
• Takai, H., Wang, R. C., Takai, K. K., Yang, H. & de Lange, T. Tel2 regulates the stability of PI3K-related protein kinases. Cell 131, 1248–1259 (2007).
  Article CAS Google Scholar
• Hurov, K. E., Cotta-Ramusino, C. & Elledge, S. J. A genetic screen identifies the Triple T complex required for DNA damage signaling and ATM and ATR stability. Genes Dev. 24, 1939–1950 (2010).
  Article CAS Google Scholar
• Takai, H., Xie, Y., de Lange, T. & Pavletich, N. P. Tel2 structure and function in the Hsp90-dependent maturation of mTOR and ATR complexes. Genes Dev. 24, 2019–2030 (2010).
  Article CAS Google Scholar
• Horejsi, Z. et al. CK2 phospho-dependent binding of R2TP complex to TEL2 is essential for mTOR and SMG1 stability. Mol. Cell 39, 839–850 (2010).
  Article CAS Google Scholar
• Kaizuka, T. et al. Tti1 and Tel2 are critical factors in mammalian target of rapamycin complex assembly. J. Biol. Chem. 285, 20109–20116 (2010).
  Article CAS Google Scholar
• Hershko, A. & Ciechanover, A. The ubiquitin system. Annu. Rev. Biochem. 67, 425–479 (1998).
  Article CAS Google Scholar
• Varshavsky, A. Three decades of studies to understand the functions of the ubiquitin family. Methods Mol. Biol. 832, 1–11 (2012).
  Article CAS Google Scholar
• Bassermann, F. & Pagano, M. Dissecting the role of ubiquitylation in the DNA damage response checkpoint in G2. Cell Death Differ. 17, 78–85 (2010).
  Article CAS Google Scholar
• Cardozo, T. & Pagano, M. The SCF ubiquitin ligase: insights into a molecular machine. Nat. Rev. Mol. Cell Biol. 5, 739–751 (2004).
  Article CAS Google Scholar
• Skaar, J. R., D’Angiolella, V., Pagan, J. K. & Pagano, M. SnapShot: F Box Proteins II. Cell 137, 1358 (2009).
  Article Google Scholar
• Palumbo, A. & Anderson, K. Multiple myeloma. New Engl. J. Med. 364, 1046–1060 (2011).
  Article CAS Google Scholar
• Moreau, P. et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood 120, 947–959 (2012).
  Article CAS Google Scholar
• Rajkumar, S. V., Richardson, P. G., Hideshima, T. & Anderson, K. C. Proteasome inhibition as a novel therapeutic target in human cancer. J. Clin. Oncol. 23, 630–639 (2005).
  Article CAS Google Scholar
• Busino, L. et al. Fbxw7α- and GSK3-mediated degradation of p100 is a pro-survival mechanism in multiple myeloma. Nat. Cell Biol. 14, 375–385 (2012).
  Article CAS Google Scholar
• Bassermann, F. et al. The Cdc14B-Cdh1-Plk1 axis controls the G2 DNA-damage-response checkpoint. Cell 134, 256–267 (2008).
  Article CAS Google Scholar
• Olsen, B. B., Guerra, B., Niefind, K. & Issinger, O. G. Structural basis of the constitutive activity of protein kinase CK2. Methods Enzymol. 484, 515–529 (2010).
  Article CAS Google Scholar
• Carrasco, D. R. et al. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 9, 313–325 (2006).
  Article CAS Google Scholar
• Zhan, F. et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood 109, 1692–1700 (2007).
  Article CAS Google Scholar
• Mattioli, M. et al. Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. Oncogene 24, 2461–2473 (2005).
  Article CAS Google Scholar
• Peterson, T. R. et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 137, 873–886 (2009).
  Article CAS Google Scholar
• Hsu, P. P. et al. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317–1322 (2011).
  Article CAS Google Scholar
• Yu, Y. et al. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 332, 1322–1326 (2011).
  Article CAS Google Scholar
• Mulligan, G. et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 109, 3177–3188 (2007).
  Article CAS Google Scholar
• Rendtlew Danielsen, J. M. et al. HCLK2 is required for activity of the DNA damage response kinase ATR. J. Biol. Chem. 284, 4140–4147 (2009).
  Article Google Scholar
• Trembley, J. H., Wang, G., Unger, G., Slaton, J. & Ahmed, K. Protein kinase CK2 in health and disease: CK2: a key player in cancer biology. Cell. Mol. Life Sci.: CMLS 66, 1858–1867 (2009).
  Article CAS Google Scholar
• Litchfield, D. W. Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem. J. 369, 1–15 (2003).
  Article CAS Google Scholar
• Battistutta, R. Protein kinase CK2 in health and disease: structural bases of protein kinase CK2 inhibition. Cell. Mol. Life Sci.: CMLS 66, 1868–1889 (2009).
  Article CAS Google Scholar
• Fernandez-Saiz, V. & Buchberger, A. Imbalances in p97 co-factor interactions in human proteinopathy. EMBO Rep. 11, 479–485 (2010).
  Article CAS Google Scholar
• Bassermann, F. et al. NIPA defines an SCF-type mammalian E3 ligase that regulates mitotic entry. Cell 122, 45–57 (2005).
  Article CAS Google Scholar
• Dorrello, N. V. et al. S6K1- and βTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science 314, 467–471 (2006).
  Article CAS Google Scholar
• Bassermann, F. et al. Multisite phosphorylation of nuclear interaction partner of ALK (NIPA) at G2/M involves cyclin B1/Cdk1. J. Biol. Chem. 282, 15965–15972 (2007).
  Article CAS Google Scholar
• Stein, G. H. T98G: an anchorage-independent human tumor cell line that exhibits stationary phase G1 arrest in vitro. J. Cell Physiol. 99, 43–54 (1979).
  Article CAS Google Scholar
• Lisztwan, J. et al. Association of human CUL-1 and ubiquitin-conjugating enzyme CDC34 with the F-box protein p45(SKP2): evidence for evolutionary conservation in the subunit composition of the CDC34-SCF pathway. EMBO J. 17, 368–383 (1998).
  Article CAS Google Scholar
• Meredith, M. J. Rat hepatocytes prepared without collagenase: prolongedretention of differentiated characteristics in culture. Cell Biol. Toxicol. 4, 405–425 (1988).
  Article CAS Google Scholar
• Busino, L. et al. SCFFbxl3 controls the oscillation of the circadian clock by directing the degradation of cryptochrome proteins. Science 316, 900–904 (2007).
  Article CAS Google Scholar
• Becker, K. F. et al. Quantitative protein analysis from formalin-fixed tissues: implications for translational clinical research and nanoscale molecular diagnosis. J. Pathol. 211, 370–378 (2007).
  Article CAS Google Scholar
• Wolff, C., Schott, C., Malinowsky, K., Berg, D. & Becker, K. F. Producing reverse phase protein microarrays from formalin-fixed tissues. Methods Mol. Biol. 785, 123–140 (2011).
  Article CAS Google Scholar